David S Saleh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David S Saleh has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexa Marr
Department of Pediatrics, Windsor Regional Hospital , 1995 Lens Avenue, Windsor, ON, Canada N8W 1L9
1 shared publication - Amy Chambers
Newborn Screening Ontario , 415 Smyth Road, Ottawa, ON, Canada K1H 8M8
1 shared publication - Danny Jomaa
School of Medicine, Queen’s University, Kingston, ON, Canada
1 shared publication - Diane K. Wherrett
Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada
1 shared publication - Emeril Santander
Newborn Screening Ontario , 415 Smyth Road, Ottawa, ON, Canada K1H 8M8
1 shared publication - Erika Bariciak
Department of Pediatrics, Children's Hospital of Eastern Ontario , 401 Smyth Road, Ottawa, ON, Canada K1H 8L1
1 shared publication
Latest Publications
- Open Access
- 9 October 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (1) , bvaf157
Improved Performance of Newborn Screening for Congenital Adrenal Hyperplasia Using 21-deoxycortisol Measurement
Purpose: Newborn screening for 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) has a high false-positive rate. A second-tier steroid profile using liquid chromatography mass spectrometry can improve specificity. Multiple screening algorithms were evaluated to optimize the performance of screening for salt-wasting CAH (SW-CAH). Methods: Principal components analysis guided potential combinations of steroid biomarkers for evaluation in a study population of 1710 immunoassay-positive samples proceeding to the second-tier steroid profile in the Newborn Screening Ontario program between August 2020 and April 2023. A Monte Carlo simulation was used to evaluate the performance of algorithms and cutoffs. Results: Optimal performance for the identification of SW-CAH used a 3-component second-tier algorithm: detectable 21-deoxycortisol (≥ 2.1 nmol/L); 17-hydroxyprogesterone + 21-deoxycortisol ≥ 40 nmol/L; and ratio of (17-hydroxyprogesterone + 21-deoxycortisol)/cortisol ≥ 0.3. All 8 cases of SW-CAH were accurately identified with a positive predictive value of 70% and 100% sensitivity for SW-CAH, whereas 1 known case of simple virilizing (SV) CAH screened negative. When applied to 26 historical cases, the algorithm identified all 13 cases of SW-CAH and all 6 SV-CAH cases, whereas other forms of CAH were filtered out because of low 21-deoxycortisol. Conclusion: Using 21-deoxycortisol for second-tier screening and applying a 3-component algorithm can improve performance of newborn screening for SW-CAH, reducing burden on patients and the health care system. Although cases of SV-CAH may be identified, the thresholds were set to identify life-threatening SW-CAH with a high positive predictive value and 100% sensitivity.
- 9 October 2025
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (1) , bvaf157
Open AccessImproved Performance of Newborn Screening for Congenital Adrenal Hyperplasia Using 21-deoxycortisol Measurement
Purpose: Newborn screening for 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) has a high false-positive rate. A second-tier steroid profile using liquid chromatography mass spectrometry can improve specificity. Multiple screening algorithms were evaluated to optimize the performance of screening for salt-wasting CAH (SW-CAH). Methods: Principal components analysis guided potential combinations of steroid biomarkers for evaluation in a study population of 1710 immunoassay-positive samples proceeding to the second-tier steroid profile in the Newborn Screening Ontario program between August 2020 and April 2023. A Monte Carlo simulation was used to evaluate the performance of algorithms and cutoffs. Results: Optimal performance for the identification of SW-CAH used a 3-component second-tier algorithm: detectable 21-deoxycortisol (≥ 2.1 nmol/L); 17-hydroxyprogesterone + 21-deoxycortisol ≥ 40 nmol/L; and ratio of (17-hydroxyprogesterone + 21-deoxycortisol)/cortisol ≥ 0.3. All 8 cases of SW-CAH were accurately identified with a positive predictive value of 70% and 100% sensitivity for SW-CAH, whereas 1 known case of simple virilizing (SV) CAH screened negative. When applied to 26 historical cases, the algorithm identified all 13 cases of SW-CAH and all 6 SV-CAH cases, whereas other forms of CAH were filtered out because of low 21-deoxycortisol. Conclusion: Using 21-deoxycortisol for second-tier screening and applying a 3-component algorithm can improve performance of newborn screening for SW-CAH, reducing burden on patients and the health care system. Although cases of SV-CAH may be identified, the thresholds were set to identify life-threatening SW-CAH with a high positive predictive value and 100% sensitivity.
- 28 July 2020
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 26 (5) , 261-263
An 11-month old with failure to thrive
An 11-month-old boy with failure to thrive presented with a 5-month history of 400 g weight loss. He exclusively breastfed and did not tolerate solids. There was no vomiting, reflux, diarrhea, or atopy. Parents reported 6 weeks of poor feeding, intermittent fever, and decreased urination. Two days prior, he had penile discharge and urine culture confirmed Group B Streptococcus urinary tract infection (UTI).
- 28 July 2020
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 26 (5) , 261-263
An 11-month old with failure to thrive
An 11-month-old boy with failure to thrive presented with a 5-month history of 400 g weight loss. He exclusively breastfed and did not tolerate solids. There was no vomiting, reflux, diarrhea, or atopy. Parents reported 6 weeks of poor feeding, intermittent fever, and decreased urination. Two days prior, he had penile discharge and urine culture confirmed Group B Streptococcus urinary tract infection (UTI).